Efficacy and Hematologic Toxicity of Salvage Chemotherapy Following Stem Cell-Supported High-Dose Chemotherapy in Women with Recurrent Ovarian Cancer
- 1 April 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (1) , 48-54
- https://doi.org/10.1006/gyno.1999.5710
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinomaCurrent Opinion in Obstetrics and Gynecology, 1999
- Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular LymphomaJournal of Clinical Oncology, 1999
- Dose-intensity in ovarian carcinoma: hold, enough?Journal of Clinical Oncology, 1997
- High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.Journal of Clinical Oncology, 1997
- High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.Journal of Clinical Oncology, 1997
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990